St Louis, Missouri, United States Gilead Group appeared to be the VC, which was created in 2003. The fund was located in North America if to be more exact in United States. The main office of represented VC is situated in the St Louis.
The top activity for fund was in 2008. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in less than 2 investment rounds annually. The increased amount of exits for fund were in 2019.
Besides them, we counted 1 critical employee of this fund in our database.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most successful fund investment fields, there are Therapeutics, Software. The fund has no exact preference in some founders of portfolio startups. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Agilis Systems, Hookipa Pharma
The standard case for the fund is to invest in rounds with 6 partakers. Despite the Gilead Group, startups are often financed by Takeda Ventures, Sofinnova Partners, Forbion Capital Partners. The meaningful sponsors for the fund in investment in the same round are Takeda Ventures, Sofinnova Partners, Sirona Capital. In the next rounds fund is usually obtained by Takeda Ventures, Spectrum Equity, Samsara BioCapital.
Funds with similar focus
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Hookipa Pharma | $60M | 11 Dec 2017 | Vienna, Austria | ||
Agilis Systems | $5M | 16 May 2008 | City of Saint Louis, Missouri, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Hookipa Pharma | $60M | 11 Dec 2017 | Vienna, Austria | ||
Agilis Systems | $5M | 16 May 2008 | City of Saint Louis, Missouri, United States |
